SLC31A2 and ovarian carcinoma: It has also been established that in patients with ovarian cancer, high levels of mRNA encoding the CTR1 protein correlate with longer disease-free survival, while low levels of the CTR2 protein correlate with better outcomes of cisplatin therapy [48].